Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28720851 | 0.87 | HTR2C (0.39) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL8301875 | 0.78 | KDM4E (0.51) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL3177100 | 0.77 | KCNH2 (0.43) | CYP3A4HTR2AHTR2CHTR2BTSHR | |
| SCHEMBL30040451 | 0.74 | CYP3A4 (0.59) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL1705264 | 0.74 | CYP3A4 (0.59) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL9871800 | 0.72 | CYP3A4 (0.56) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL31193341 | 0.72 | CYP3A4 (0.56) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL6785200 | 0.72 | MAPT (0.46) | ALDH1A1MAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL11988468 | 0.69 | HTR2A (0.40) | ALDH1A1CYP3A4HTR2AHTR2CHTR2B | |
| SCHEMBL3178174 | 0.69 | MRGPRX2 (0.46) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844045-B1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-11-04 | — | — | EP | disclosed |
| EP-1461337-B1 | PYRIDO¬2,1-A ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7442710-B2 | Substituted phenyl methanones | HOFFMAN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1844045-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079467-A1 | PHENYL METHANONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER 1 INHIBITORS | F. HOFMANN-LA ROCHE AG (CH) | 2006-08-03 | — | — | WO | disclosed |
| US-20060167023-A1 | Substituted phenyl methanones | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| US-6897222-B2 | Pyrido[2,1-a]isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1461337-A1 | PYRIDO[2,1-A]ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-29 | — | — | EP | disclosed |
| US-20040176406-A1 | Pyrido [2,1-a] isoquinoline derivatives | GOBBI LUCA CLAUDIO (CH) | 2004-09-09 | — | — | US | disclosed |
| US-6727261-B2 | BENZO(A)QUINOLIZINE DERIVATIVES FOR DIABETES AND NON-ISULIN DEPENDENT DIABETES TREATMENT | HOFFMAN-LA ROCHE INC. | 2004-04-27 | — | — | US | disclosed |
| EP-1186601-B1 | NOVEL ISOQUINOLINE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-20030149071-A1 | Pyrido [2,1-a] isoquinoline derivatives | HOFFMANN-LA ROCHE INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003055881-A1 | PYRIDO(2,1-A)ISOQUINOLINE DERIVATIVES AS DPP-IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-10 | — | — | WO | disclosed |
| US-6573279-B1 | Drug, particularly to a novel isoquinoline derivative or its salt having an If current inhibitory effect without serious side effects such as convulsion and also to a drug, particularly a cardiac rate lowering agent, containing the | ASTELLAS PHARMA INC. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1186601-A1 | NOVEL ISOQUINOLINE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149071-A1 | Pyrido [2,1-a] isoquinoline derivatives | DPP4, DPP7, DPP3 | ALDH1A1 84/4885MAPT 4151/4885CYP3A4 44/4885 |
| US-20060167023-A1 | Substituted phenyl methanones | SLC6A7, SLC1A1, SLC26A3 | ALDH1A1 1405/4885MAPT 751/4885CYP3A4 535/4885 |
| US-20040176406-A1 | Pyrido [2,1-a] isoquinoline derivatives | DPP4, DPP7, DPP3 | ALDH1A1 84/4885MAPT 4151/4885CYP3A4 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.